Market Access Reuters Europe 2025: Using value propositions to improve acc... In a Reuters Pharma Europe 2025 fireside chat, NICE Advice Director Brad Grove spoke with Novartis's Matic Meglic about novel pharma payment models.
News Novartis plans $23bn manufacturing, R&D spend in US Novartis has announced a massive investment in manufacturing and R&D facilities in the US so it can make "100% of its key medicines" there.
News Novartis gets FDA nod for second of three IgAN drugs Novartis has claimed accelerated approval in the US for Vanrafia, one of a trio of drugs it hopes will revolutionise the treatment of IgA nephropathy.
News Fabhalta is first FDA-approved therapy for rare disease C3G Novartis' oral complement inhibitor Fabhalta has become the first approved treatment for rare kidney disease C3G as it chases a $3bn sales target.
News Novartis sheds staff as Entresto patent expiry looms Novartis will cut 427 jobs this year in the US as it prepares for the loss of market exclusivity for its blockbuster heart failure therapy Entresto.
News Novartis builds in cardiovascular with $3.1bn Anthos buy Novartis has agreed to buy Anthos from private equity firm Blackstone for $3.1 billion, taking Factor XI inhibitor abelacimab back in-house.
Market Access New FDA head says no more pharma on advisory committees The announcement signals a new administration attempting to distance itself from industry, but the actual impact seems small.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl